Pharma Supplier Hub

My Green Lab is a nonprofit organization that sets global benchmarks for sustainable scientific research through lab certifications, product ecolabels, and training. Its My Green Lab Certification and ACT Ecolabel help labs and manufacturers reduce environmental impact and guide responsible purchasing across the life-science ecosystem.

N4 Pharma is a specialist pharmaceutical company developing Nuvec®, a novel silica nanoparticle gene delivery platform for oncology, gene therapy and vaccines. It collaborates with pharma and biotech partners to apply Nuvec® and related technologies to nucleic acid therapeutics, aiming to improve targeting, stability and efficacy of advanced therapies.

Nanion Technologies is a Munich-based provider of electrophysiology and cell analytics instrumentation for drug discovery and research. Its portfolio covers automated patch clamp, membrane biophysics, consumables, and support services for academic, CRO, and pharma buyers.

Leon-nanodrugs GmbH (LEON) is a Germany-based pharmatech company that develops FR-JET® mixer-based NANO® equipment for nanoparticle manufacturing from R&D to GMP. Its NANOscreen®, NANOlab®, NANOme® and NANOus® systems, combined with formulation and process development services and flexible leasing, help pharma, biotech, and CDMOs scale lipid nanoparticle and other nanomedicine processes efficiently.

UPM Biomedicals, part of UPM, supplies patented nanofibrillar cellulose biomaterials for life science research and medical devices, including GrowDex, GrowDase, GrowInk, FibDex and FibGel. Its animal‑free, birch‑derived hydrogels and dressings are manufactured under ISO 13485 and supported by protocol and workflow integration services for pharma, biotech and medtech customers.

Oxford Nanopore Technologies (Nanoporetech) provides nanopore-based DNA/RNA sequencing platforms, library prep kits and analysis software for real-time, information‑rich genomics. Its scalable devices, including the portable MinION and high‑output PromethION flow cells, support applications such as cancer research, hereditary disease, microbiology and metagenomics, with diagnostics‑oriented offerings under Oxford Nanopore Diagnostics.

NanoTemper Technologies is a founder-owned biophysical characterization company providing instruments, consumables, and reagents for binding affinity and protein stability analysis across discovery and development. With systems like Prometheus Panta, Monolith, Dianthus and Andromeda, NanoTemper helps pharma and biotech teams obtain high-precision, reproducible in-solution data for biologics, targeted protein degradation, and complex membrane proteins, supported by global locations in Munich and South San Fr

NanoTemper Technologies is a privately held biophysical instrumentation company that provides binding affinity, protein stability, and high‑throughput screening solutions for biologics and complex targets. Headquartered in Munich with global offices, it offers instruments, consumables, and reagents designed for high precision, reproducibility, and seamless workflow integration from discovery to regulatory filing.

Nanoworx is a Netherlands-based CRO specializing in advanced nanomedicine development. It offers nanoparticle design, high-throughput screening, scale-up, manufacturing, and in vitro characterization for academic and industry clients.

MetP Pharma AG is a private Swiss company specializing in nose‑to‑brain nasal drug delivery, built around its MetP platform combining Silcum gel formulation, Lecticula single‑dose nasal device and Maxima filling technology. The company supports partners with enabling technology for CNS and systemic delivery and has in‑house OTC and prescription nasal products across allergic rhinitis, testosterone replacement, ADHD, MS, mild cognitive impairment, insomnia and concussion, with at least one product already ma

Ncardia is a global iPSC technology company supplying iPSC-derived cell models, cardiac and neural assays, and custom iPSC platforms for drug discovery and cell therapy. With products like Ncyte® vCardiomyocytes and multi-tissue IO safety panels, it supports more predictive screening, long-term lot consistency and scalable manufacturing for pharma and biotech R&D.

Nemesys and Cobomation by CETONI deliver modular syringe pump–based flow systems and automation solutions built around the CETONI Elements software platform. Their Nemesys pumps provide pulseless, sub-nanoliter liquid dosing for microfluidics and precision dosing across biology, chemistry, geology and industrial applications. With configurable modules, accessories and SDK-based integration, CETONI targets customers needing customized, tightly integrated microfluidic and dosing workflows.

CETONI GmbH (Nemesys and Cobomation) is a German provider of high‑precision syringe pumps, modular microfluidic flow systems and automation solutions for research and industrial dosing. Its Nemesys S, M and ultra‑high‑pressure modules deliver pulsation‑free flow from sub‑nanoliter dosing up to 1000 bar, all controlled via CETONI Elements software and integrable through the CETONI SDK.

NEOsphere Biotechnologies GmbH is a Germany-based proteomics company specializing in targeted protein degradation and induced proximity drug discovery. It offers deep proteomic screening, global ubiquitinomics, high-throughput interactomics, activity-based protein profiling, and AI-powered data analysis to support hit discovery, lead optimization, and mechanistic validation of degrader and proximity-inducing molecules.

NervGen Pharma Corp. is a Vancouver-based, Nasdaq-listed clinical-stage biopharmaceutical company founded in 2017, developing neuroreparative therapeutics for spinal cord injury and neurodegenerative diseases. Its lead candidate NVG-291 has FDA Fast Track and EMA Orphan Designations and is in Phase 3 development.

Neurolentech is an Austrian biotech spin-out from IST Austria that develops patient-derived neuronal cell models to accelerate drug discovery for neurodevelopmental disorders such as epilepsy, severe autism and intellectual disability. Using iPSC-based brain cell models and proprietary functional assays, the company identifies new drug targets and supports biopharma partners with disease-relevant screening platforms and collaborative NDD research.

EXO Biologics is a Belgian clinical-stage biotech developing exosome-based nanomedicine therapies for rare inflammatory and respiratory diseases, with a lead focus on bronchopulmonary dysplasia in preterm babies. The company combines a proprietary GMP exosome manufacturing platform, advanced drug loading and delivery technologies, and CDMO services to support both its own pipeline and external partners from research to clinical development.

Nicoya Lifesciences Inc. is a private Canadian company providing advanced label-free biophysical tools for protein binding, structure, stability, and kinetics. Its portfolio includes digital SPR platforms (Alto, Revo, OpenSPR), the FastHDX millisecond HDX‑MS protein dynamics platform, and complementary CD, DSF, and kinetics systems, serving pharma, biotech, and academic R&D teams worldwide.

Nona Biosciences is a private biotechnology company in Cambridge, Massachusetts, offering fully human antibody discovery and integrated biotherapeutic development services. Its portfolio includes Harbour Mice® HCAb/H2L2, Hu-mAtrIx™ AI discovery, NonaCarFx™, and Modalities-on-Demand® for ADCs, bispecifics, CAR-based cell therapy, mRNA, siRNA, and BBB delivery.

Noramco is a small-molecule API and drug substance manufacturer that has been acquired and integrated into the Siegfried Group’s CDMO network. Its former operations now function as Siegfried drug substance sites in the US and Australia, contributing high-quality small-molecule capacity and reliable API supply for pharmaceutical customers.

Noramco is a small‑molecule API and drug‑substance specialist that has been acquired and integrated into the Siegfried Group, a global CDMO. Its former operations and capabilities now operate under Siegfried’s API and CDMO platform, and buyers should source Noramco’s legacy offerings via Siegfried.

ORYL Photonics is a Swiss life-science instrumentation company that developed the ORYL F1, a plate-based, high-throughput solubility and aggregation profiling platform powered by Ultrafast Light Scattering. The instrument and associated measurement services help pharma and biotech teams rapidly de-risk solubility and aggregation across discovery and formulation using minimal compound and standard 384-well workflows.

Obatala Sciences is a New Orleans life-science supplier founded in 2017, focused on human-derived research tools for obesity, diabetes, cancer, regenerative medicine, and tissue engineering. Its offering includes ObaCell organ-on-a-chip platforms, ObaGel human-derived hydrogels, diverse stem cell products, specialized culture media, and contract research services for industry, academia, and government labs.

Objective Biotechnology is a private biotechnology tools company in Minneapolis developing automated microinjection and neurotechnology platforms for high-throughput genetic and neuroscience research. Its Autoinjector robotic system uses computer vision and machine learning to automate embryo microinjection across species, while its neurotechnology tools provide cortex-wide optical access and recordings in unrestrained rodent models.